MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected ...

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

Merck & Co., Inc. (NYSE:MRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Merck & Co., Inc. (NYSE:MRK) has ...

Merck & Co., Inc. (NYSE: MRK) is one of the best depressed stocks to buy in 2025. On August 2, the company completed the ...

Merck (MRK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts ...

IO Biotech said on Monday its experimental combination cancer vaccine helped slow the disease's progression in a late-stage ...

The group lifted its full-year guidance for growth in underlying earnings, due to better prospects for its life-sciences and healthcare segments, but was more cautious on sales.

With U.S. markets hovering near record highs, many investors are turning to dividend-paying stocks as a way to balance growth ...

Novo Nordisk, GSK and others need to replenish their pipelines to replace drugs coming off patent. In the past, buying a promising biotech required paying a 100% premium. But high interest rates and ...

Denmark-based IO Biotech’s shares traded 51% higher ahead of the morning bell at $2.74 after the company said that Cylembio ...

Repay Holdings Corporation (NASDAQ: RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing ...